Eurofins Scientific SE (ERFSF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ERFSF representa a Eurofins Scientific SE, una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 18 mar 2026Eurofins Scientific SE (ERFSF) Resumen de Asistencia Médica y Tuberías
Eurofins Scientific SE is a global leader in analytical testing and laboratory services, providing a comprehensive suite of solutions across diverse sectors, including food, environment, pharmaceuticals, and consumer products. The company's extensive network and scientific expertise position it as a key player in ensuring safety and quality standards worldwide.
Tesis de Inversión
Eurofins Scientific SE presents a compelling investment case due to its diversified service offerings and global presence in the analytical testing market. With a market capitalization of $12.91 billion, the company benefits from a stable revenue stream driven by regulatory requirements and increasing consumer demand for safety and quality. A gross margin of 22.5% and an ROE of 9.5% indicate solid profitability. Ongoing: The company's strategic acquisitions and expansion into high-growth areas such as biopharma and environmental testing are expected to drive future revenue growth. However, a debt-to-equity ratio of 96.84 and a beta of 0.94 suggest moderate financial risk and market sensitivity.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $12.91 billion reflects its significant presence in the analytical testing market.
- Profit margin of 6.5% indicates moderate profitability within the competitive diagnostics and research sector.
- Gross margin of 22.5% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Return on Equity (ROE) of 9.5% suggests efficient utilization of shareholder equity to generate profits.
- Debt-to-Equity ratio of 96.84 indicates a relatively high level of financial leverage.
Competidores y Pares
Fortalezas
- Global presence with an extensive network of laboratories.
- Diversified service offerings across multiple industries.
- Strong reputation for scientific expertise and quality.
- Proven track record of strategic acquisitions and growth.
Debilidades
- High debt-to-equity ratio.
- Exposure to regulatory changes and compliance risks.
- Dependence on acquisitions for growth.
- Potential for price competition in certain markets.
Catalizadores
- Upcoming: Expansion of biopharma testing services to capitalize on the growing biopharmaceutical industry.
- Ongoing: Strategic acquisitions to expand service offerings and geographic reach.
- Ongoing: Increasing focus on environmental testing to meet growing demand for environmental monitoring.
- Ongoing: Leveraging technological advancements to improve efficiency and accuracy of testing processes.
Riesgos
- Potential: High debt-to-equity ratio could limit financial flexibility.
- Potential: Changes in regulatory requirements and compliance standards could increase costs.
- Potential: Economic downturns could reduce spending on testing services.
- Ongoing: Intense competition from other testing laboratories could put pressure on pricing.
- Potential: Product liability claims and recalls could damage reputation and financial performance.
Oportunidades de crecimiento
- Expansion in Biopharma Testing: The biopharmaceutical industry is experiencing rapid growth, driven by the development of novel therapies and increasing regulatory scrutiny. Eurofins can capitalize on this trend by expanding its biopharma testing services, including drug discovery, clinical trials, and quality control. The global biopharmaceutical testing market is projected to reach $120 billion by 2027, offering significant growth potential for Eurofins. Timeline: Ongoing.
- Increasing Focus on Environmental Testing: Growing concerns about environmental pollution and climate change are driving demand for environmental testing services. Eurofins can leverage its expertise in water, air, and soil testing to capture a larger share of this market. The global environmental testing market is expected to reach $35 billion by 2026, presenting a substantial opportunity for Eurofins. Timeline: Ongoing.
- Growth in Food Safety Testing: With increasing consumer awareness of food safety and stricter regulations, the demand for food testing services is growing. Eurofins can expand its food testing capabilities, including allergen testing, GMO testing, and pesticide residue testing, to meet this demand. The global food safety testing market is projected to reach $22 billion by 2025, providing a significant growth avenue for Eurofins. Timeline: Ongoing.
- Penetration of Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid economic growth and increasing demand for testing and analytical services. Eurofins can expand its presence in these markets through strategic acquisitions and partnerships. The growth in these regions offers substantial opportunities for Eurofins to increase its global market share. Timeline: Ongoing.
- Strategic Acquisitions: Eurofins has a history of growth through strategic acquisitions. By acquiring smaller testing laboratories and specialized service providers, Eurofins can expand its service offerings, geographic reach, and customer base. This strategy allows Eurofins to quickly enter new markets and gain access to specialized expertise. Timeline: Ongoing.
Oportunidades
- Expansion in high-growth areas such as biopharma and environmental testing.
- Penetration of emerging markets with increasing demand for testing services.
- Leveraging technological advancements to improve efficiency and accuracy.
- Increasing outsourcing of testing services by large corporations.
Amenazas
- Economic downturns and reduced spending on testing services.
- Increased competition from other testing laboratories.
- Changes in regulatory requirements and compliance standards.
- Potential for product liability claims and recalls.
Ventajas competitivas
- Extensive network of laboratories across the globe.
- Wide range of testing services across various industries.
- Strong reputation for scientific excellence and customer service.
- Strategic acquisitions to expand service offerings and geographic reach.
Acerca de ERFSF
Founded in 1987 and headquartered in Luxembourg, Eurofins Scientific SE has grown from a small food testing laboratory to a global leader in analytical testing and laboratory services. The company's initial focus on food authenticity testing has expanded significantly to encompass a wide range of industries, including pharmaceuticals, environmental science, agriculture, and consumer products. Eurofins provides services such as agroscience, biopharma, clinical diagnostics, and consumer product testing. Its offerings include biological assessment, consumer and human safety testing, product chemistry, regulatory consultancy, and seed services. The company also provides assurance services, including sustainability audits, certification, quality inspection, and food and dietary supplement labeling. Eurofins operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste. It also offers specialized testing services such as forensic, genomic, maritime, materials and engineering, and sensory and consumer services. Eurofins' commitment to scientific excellence and customer service has driven its growth, making it a trusted partner for businesses seeking to ensure the safety, quality, and compliance of their products and processes.
Qué hacen
- Provides analytical testing services for food, environment, pharmaceutical, and consumer products.
- Offers laboratory services, including water, air, and soil testing.
- Conducts biological assessments and product chemistry testing.
- Provides regulatory consultancy and seed services.
- Offers sustainability audits, certification, and quality inspection services.
- Provides clinical diagnostics and biopharma testing services.
- Offers forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services.
Modelo de Negocio
- Generates revenue by providing analytical testing and laboratory services to various industries.
- Offers a wide range of testing services, including food, environment, pharmaceutical, and consumer products.
- Operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste.
- Acquires smaller testing laboratories and specialized service providers to expand its service offerings and geographic reach.
Contexto de la Industria
Eurofins Scientific SE operates in the diagnostics and research industry, which is characterized by increasing demand for testing and analytical services driven by stringent regulatory requirements and growing consumer awareness of safety and quality. The global market for testing, inspection, and certification is projected to reach $250 billion by 2028, growing at a CAGR of 4.5%. Eurofins competes with companies such as SGS SA, Intertek Group, and Bureau Veritas, offering a wide range of testing services across various sectors. The industry is also influenced by technological advancements, such as automation and data analytics, which are improving the efficiency and accuracy of testing processes.
Clientes Clave
- Food manufacturers and processors
- Pharmaceutical companies
- Environmental agencies and organizations
- Consumer product manufacturers
- Government agencies
Finanzas
Gráfico e información
Precio de la acción de Eurofins Scientific SE (ERFSF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 4 dic 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ERFSF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ERFSF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ERFSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de ERFSF
ERFSF cotiza en el nivel de mercado OTC Other de OTC Markets.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
ERFSF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar ERFSF?
Eurofins Scientific SE (ERFSF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Global presence with an extensive network of laboratories.. Riesgo principal a monitorear: Potential: High debt-to-equity ratio could limit financial flexibility.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ERFSF?
ERFSF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ERFSF?
Los precios de ERFSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ERFSF?
La cobertura de analistas para ERFSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ERFSF?
Las categorías de riesgo para ERFSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: High debt-to-equity ratio could limit financial flexibility.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ERFSF?
La relación P/E para ERFSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ERFSF sobrevalorada o infravalorada?
Determinar si Eurofins Scientific SE (ERFSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ERFSF?
Eurofins Scientific SE (ERFSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- The information provided in this dossier is based on available data and analysis as of March 18, 2026. Market conditions and company performance may change over time.
- AI analysis is pending and may provide further insights into the company's performance and prospects.